News1 day ago
KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors
DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab, was well tolerated and demonstrated durable responses Dose was determined for Phase II...
